Literature DB >> 8099797

Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease.

A Y Deutch1.   

Abstract

The dopaminergic innervation of the prefrontal cortex is able to transsynaptically regulate the activity of subcortical dopamine innervations. Disruption of the prefrontal cortical DA innervation results in the enhanced biochemical responsiveness of the dopamine innervation of the nucleus accumbens. We present recent data indicating that distinct prefrontal cortical dopamine innervations can be functionally dissociated on the basis of responsiveness to stress. The ventral striatal projection target (nucleus accumbens shell) of the prefrontal cortical region that is stress sensitive is also responsive to stress. In this manner interconnected cortico-striato-pallido-mesencephalic loops can be defined on the basis of the biochemical responsive of local dopamine systems to stress and on the basis of responsiveness to antipsychotic drugs. These data suggest the functional derangement of a distinct corticofugal loops in schizophrenia and in certain aspects of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099797     DOI: 10.1007/bf01245232

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  120 in total

1.  Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat.

Authors:  H W Berendse; Y Galis-de Graaf; H J Groenewegen
Journal:  J Comp Neurol       Date:  1992-02-15       Impact factor: 3.215

Review 2.  Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia.

Authors:  A Y Deutch; B Moghaddam; R B Innis; J H Krystal; G K Aghajanian; B S Bunney; D S Charney
Journal:  Schizophr Res       Date:  1991 Mar-Apr       Impact factor: 4.939

3.  Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease.

Authors:  S J Kish; K Shannak; A Rajput; J H Deck; O Hornykiewicz
Journal:  J Neurochem       Date:  1992-02       Impact factor: 5.372

4.  Opposite influences of dopaminergic pathways to the prefrontal cortex or the septum on the dopaminergic transmission in the nucleus accumbens. An in vivo voltammetric study.

Authors:  A Louilot; M Le Moal; H Simon
Journal:  Neuroscience       Date:  1989       Impact factor: 3.590

Review 5.  Telencephalic projections of the A8 dopamine cell group.

Authors:  A Y Deutch; M Goldstein; F Baldino; R H Roth
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

6.  Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat.

Authors:  C J Pycock; C J Carter; R W Kerwin
Journal:  J Neurochem       Date:  1980-01       Impact factor: 5.372

7.  An anatomy of schizophrenia?

Authors:  J R Stevens
Journal:  Arch Gen Psychiatry       Date:  1973-08

8.  Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin.

Authors:  S R Sesack; A Y Deutch; R H Roth; B S Bunney
Journal:  J Comp Neurol       Date:  1989-12-08       Impact factor: 3.215

Review 9.  Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates.

Authors:  B Berger; P Gaspar; C Verney
Journal:  Trends Neurosci       Date:  1991-01       Impact factor: 13.837

10.  Experiences of long-term treatment with remoxipride: efficacy and tolerability.

Authors:  J Wålinder; A C Holm
Journal:  Acta Psychiatr Scand Suppl       Date:  1990
View more
  36 in total

1.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats.

Authors:  Svetlana Semenova; Daniel Hoyer; Mark A Geyer; Athina Markou
Journal:  Neuropeptides       Date:  2010-10       Impact factor: 3.286

Review 3.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 4.  Opponency revisited: competition and cooperation between dopamine and serotonin.

Authors:  Y-Lan Boureau; Peter Dayan
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

5.  Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

Authors:  M E Stockton; K Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 6.  Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective.

Authors:  Antonio Alcaro; Robert Huber; Jaak Panksepp
Journal:  Brain Res Rev       Date:  2007-08-21

7.  The dopaminergic nigrostriatal system in sleep deprivation in cats.

Authors:  G A Oganesyan; E A Aristakesyan; I V Romanova; V A Belova; I V Artamokhina
Journal:  Neurosci Behav Physiol       Date:  2008-09-18

Review 8.  The effects of stress on central dopaminergic neurons: possible clinical implications.

Authors:  J M Finlay; M J Zigmond
Journal:  Neurochem Res       Date:  1997-11       Impact factor: 3.996

9.  Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment.

Authors:  B L Murphy; A F Arnsten; J D Jentsch; R H Roth
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

10.  Cholecystokinin activates CCKB receptors to excite cells and depress EPSCs in the rat rostral nucleus accumbens in vitro.

Authors:  Samuel B Kombian; Kethireddy V V Ananthalakshmi; Subramanian S Parvathy; Wandikayi C Matowe
Journal:  J Physiol       Date:  2003-12-12       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.